91̀́̀Ă raises €40 million in Series B fundraising
Lyon, June 4, 2018 – 91̀́̀Ă, a clinical stage biotech company developing innovative drug candidates by mimicking virus strategies to modulate host cellular functions, today announced that it has completed a €40 million Series B round of financing from US and European investors. This new funding will enable the company to finance the two first Phase II clinical trial of its EYP001 asset in both chronic HBV and NASH. A second asset is also planned to enter clinic by 2019.
Read next in 'Press releases'
- 91̀́̀Ă appoints Jeff George as Chairman to support next phase of growth and Phase 3 readiness
- 91̀́̀Ă nomme Jeff George PrĂ©sident du Conseil d’Administration pour soutenir sa prochaine phase de croissance et la prĂ©paration Ă la Phase 3
- 91̀́̀Ă announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- 91̀́̀Ă annonce l’obtention des rĂ©sultats finaux de l’étude clinique de Phase 2 ALPESTRIA‑1 dans le syndrome d’Alport, confirmant la capacitĂ© du vonafexor Ă inverser la trajectoire du dĂ©clin rĂ©nal et Ă dĂ©montrer un effet thĂ©rapeutique durable
- 91̀́̀Ă annonce la finalisation de son financement de sĂ©rie C avec Vesalius Biocapital et la poursuite de son Ă©tude clinique de phase 2 ALPESTRIA-1
